Sales & Marketing News | pharmaphorum

News

SCOTUS won’t hear ‘skinny label’ lawsuit

The US Supreme Court has refused to look at the result of a federal lawsuit between GSK and Teva over so-called ‘skinny labels’ for generic drugs, despite a request from t

News

Babylon retreats from public listing as losses climb

Shares in Babylon Health were pummelled yesterday after it said it would go back into private hands and withdrew its financial forecasts for the year.

News

GSK et al win another round in Zantac cancer litigation

GSK and other drugmakers fending off litigation claiming that gastrointestinal drug Zantac or a generic caused cancer have won a supreme court ruling in Canada, after also

News

FDA clears Rexulti as first drug for Alzheimer’s agitation

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege

News

Changing Faces: Pharma and biotech hires from April 2023

The month of April was a bit lighter in quantity of hires, but those we did see were high-profile: pharma and biotech saw at least four CEO changes, as well as numerous board chairs.

News

Investment group will take Syneos Health private

Contract research organisation (CRO) Syneos Health has agreed to be acquired by a group of investors, in the second multibillion-dollar takeover of a pharma outsourcing bu

SCOTUS won’t hear ‘skinny label’ lawsuit

Babylon retreats from public listing as losses climb

GSK et al win another round in Zantac cancer litigation

FDA clears Rexulti as first drug for Alzheimer’s agitation

Changing Faces: Pharma and biotech hires from April 2023

Investment group will take Syneos Health private

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks